


Strong performance and momentum drives upgraded guidance

“We have delivered another excellent quarter of performance, with strong sales and earnings growth, notably in HIV and Vaccines, and continued strengthening of the R&D pipeline and product portfolio. The approval of *Arexvy* was an important milestone for us and is at the forefront of a next wave in vaccine innovation for GSK. Completion of the Bellus Health acquisition also strengthened our late-stage respiratory pipeline. Our momentum supports the upgrade we have made to our financial guidance for 2023 and further increases our confidence in delivering longer-term profitable growth for shareholders.”

Emma Walmsley
Chief Executive Officer, GSK



Vaccines

£2.0bn

+18%, +15%

including and excluding COVID-19 solutions

Specialty Medicines

£2.5bn

-7%, +12%

including and excluding COVID-19 solutions

General Medicines

£2.6bn

+8%

Adjusted Group operating margin

30.2%

Total EPS

40.1p +>100%

Adjusted EPS

38.8p +16%

Dividend

14p

68

vaccines and medicines in pipeline

17

pipeline assets in phase III / registration

Journalists/media see press release on www.gsk.com for full details on Q2 2023.

Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on pages 17, 19, 54 and 55 of the press release.

Product group sales may not add to total sales due to rounding.

References to growth are at constant exchange rates (CER) and for continuing operations unless stated otherwise.